El interés en corto de Dogwood Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Dogwood Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Dogwood Therapeutics (NASDAQ:DWTX) Bolsa, Informe de interés en corto

Dogwood Therapeutics

Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics Inc

XWELL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) reported quarterly losses of $(0.99) per share. This is a 64.13 percent increase over losses of $(2.76) per share from the same period last year. The company reported $8.42 million in sales this quarter. This is a 12.77 percent increase over sales of $7.47 million the same period last year.

Earnings

News

XWEL

XWELL Q3 EPS $(0.99) Up From $(2.76) YoY, Sales $8.42M Up From $7.47M YoY

Metalla Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTA#AMEX">MTA</a>) reported quarterly losses of $(0.01) per share. This is a 75 percent increase over losses of $(0.04) per share from the same period last year. The company reported $1.62 million in sales this quarter. This is a 19.35 percent increase over sales of $1.36 million the same period last year.

Metalla Royalty Q3 EPS $(0.01) Up From $(0.04) YoY, Sales $1.62M Up From $1.36M YoY

Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.51 million which missed the analyst consensus estimate of $2.61 million by 3.75 percent. This is a 22.04 percent increase over sales of $2.06 million the same period last year.

Earnings Misses

MLSS

Milestone Scientific Q3 EPS $(0.02) Misses $(0.01) Estimate, Sales $2.51M Miss $2.61M Estimate

MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) reported quarterly losses of $(1.26) per share. This is a 19.23 percent increase over losses of $(1.56) per share from the same period last year. The company reported $3.67 million in sales this quarter. This is a 733.64 percent increase over sales of $440.00 thousand the same period last year.

LIFW

MSP Recovery Q3 Adj $(1.26) Up From $(1.56) YoY, Sales $3.67M Up From $440.00K YoY

Inhibrx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBX#NASDAQ">INBX</a>) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.81) by 25.46 percent. This is a 35.31 percent increase over losses of $(4.39) per share from the same period last year.

Earnings Beats

INBX

Inhibrx Biosciences Q3 EPS $(2.84) Beats $(3.81) Estimate

CHMI

Cherry Hill Mortgage Investment Begins Operations As Fully Integrated, Internally Managed Mortgage REIT; Plans To Continue To Pursue Management's Execution Of Residential Mortgage Investment Strategy

Everi Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVRI#NYSE">EVRI</a>) ("Everi" or the "Company"), a premier provider of land-based and digital casino gaming content and products, financial technology, player loyalty solutions, and bingo, announced today that its stockholders have voted at a special meeting of Everi stockholders (the "Special Meeting") to approve the pending simultaneous acquisition of Everi and the Gaming &amp; Digital business of International Game Technology PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) by a newly formed holding company owned by funds managed by affiliates of Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) (the "Apollo Funds") through a merger. As previously announced, pursuant to the terms of the merger agreement, Everi stockholders will receive $14.25 per share in cash for every share of Everi common stock they own immediately prior to the effective time of the merger.

EVRI

Everi Announces That Its Stockholders Have Voted To Approve The Pending Simultaneous Acquisition Of Everi And The Gaming & Digital Business Of International Game Technology By A Newly Formed Holding Company Owned By Funds Managed By Affiliates Of Apollo Global Management; Everi Stockholders Will Receive $14.25 Per Share In Cash For Every Share Of Everi Common Stock They Own Immediately Prior To The Effective Time Of The Merger

GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) reported quarterly losses of $(0.67) per share. This is a 98.98 percent increase over losses of $(65.78) per share from the same period last year.

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Q3 EPS $(0.67) Up From $(65.78) YoY

The Trade Desk Stockholders Approve Reincorporation Of Company From State Of Delaware To State Of Nevada

Atlantica Sustainable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AY#NASDAQ">AY</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.42 by 66.67 percent. This is a 22.22 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $347.55 million which beat the analyst consensus estimate of $324.54 million by 7.09 percent. This is a 14.34 percent increase over sales of $303.96 million the same period last year.

Atlantica Sustainable Q3 EPS $0.14 Misses $0.42 Estimate, Sales $347.55M Beat $324.54M Estimate

XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) reported quarterly losses of $(0.13) per share. This is a 80.3 percent increase over losses of $(0.66) per share from the same period last year. The company reported $918.00 thousand in sales this quarter.

XTIA

XTI Aerospace Q3 EPS $(0.13) Up From $(0.66) YoY, Sales $918.00K

From the early days of internet forums to today's thriving Reddit communities, cannabis discussions have transformed, offering unprecedented visibility into consumer preferences.  
Caleb Chen, founder of The Highest Critic and a key moderator on Reddit's largest cannabis community, has harnessed this evolution, creating a platform that fills a crucial gap: providing unfiltered, ground-level reviews at a time when the industry is dominated by dispensary marketing.
&#8220;Reviewers on <a href="https://thehighestcritic.com/">The Highest Critic </a>aren't just casual users—they're connoisseurs buying the best cannabis, whether it's from the legal market or the underground scene,&#8221; Chen shared with Benzinga Cannabis. &#8220;Their insights offer an early look at trends, often predicting which strains will become the next big thing in dispensaries.&#8221; 
This approach of gathering authentic, ground-level feedback mirrors the spirit of early online cannabis forums, where enthusiasts first connected over shared experiences.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">From Usenet To Reddit: The Evolution Of Cannabis Conversations</h3>
Chen traces the history of online cannabis discussions back to the earliest days of the internet. &#8220;Cannabis has been part of the online conversation since the ARPANET era. At the dawn of the internet, one of the first discussions was about weed,&#8221; he explained. This legacy began with Usenet, an early online network launched in the 1980s that allowed users to exchange messages in public forums. 
Usenet was a precursor to today's social media, where cannabis enthusiasts shared growing tips, strain reviews and underground market insights. The collaborative spirit of these early forums laid the groundwork for modern platforms like Reddit, where communities continue to exchange authentic, crowd-sourced information about cannabis products.
<h3 class="wp-block-heading">A Window Into Consumer Preferences</h3>
Chen pointed out how Reddit's <a href="https://www.reddit.com/r/trees/wiki/index/?rdt=49055">r/trees subreddit offers a unique opportunity for brands</a> to gauge market trends early on. &#8220;Reviewers often get their hands on tester products from breeders before they hit<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41725186/with-200-new-dispensaries-and-four-states-voting-on-legalizing-cannabis-could-marke"> dispensaries</a>,&#8221; Chen noted. &#8220;This early feedback loop can predict which cultivars will become top sellers two or three years down the line. It's a real-time look at what heavy users are seeking.&#8221;
For brands, this is invaluable. Insights shared on The Highest Critic go beyond typical <a href="https://www.benzinga.com/topic/cannabis-marketing">dispensary marketing</a>, delving into what consumers truly want. Chen explains that while dispensaries often focus on THC levels as a selling point, Reddit users are more interested in specific effects and unique terpene profiles.
&#8220;Reddit users often look beyond the THC percentage. They want to know what's good, what's worth their money, and what provides the medicinal effects they're looking for,&#8221; Chen said. &#8220;This kind of feedback can help brands refine their offerings and focus on quality, rather than just chasing the highest THC numbers.&#8221;
Read Also:<a href="https://www.benzinga.com/general/health-care/24/11/41959233/yougov-poll-reveals-what-women-want-with-weed-relax-mindfulness-and-great-deals"> YouGov Poll Reveals What Women Want With Weed: Relax, Mindfulness And Great Deals</a>
<h3 class="wp-block-heading">Moderator Challenges</h3>
&#8220;A lot of the moderation involves banning underage users and handling posts from people looking to buy weed illegally,&#8221; Chen said. &#8220;It's a collective effort. Other moderators have been quoted in articles before, responding to inquiries through the official mod mail.&#8221; 
<h3 class="wp-block-heading">How Cannabis Brands Can Leverage Reddit For Market Insights</h3>
For cannabis brands, Reddit's communities offer a unique advantage in <a href="https://www.benzinga.com/topic/cannabis-branding">understanding market trends</a>, particularly the premiumization of cannabis. Chen explained how The Highest Critic has become a trusted resource for identifying new cultivars and genetics before they reach mainstream dispensaries.
&#8220;Many of the reviews we publish are based on tester strains from breeders or small-batch growers. These are the strains that often end up being the next big thing in dispensaries,&#8221; Chen noted. &#8220;By paying attention to what reviewers are excited about, brands can get ahead of the curve and focus on strains that have a<a href="https://www.benzinga.com/markets/cannabis/24/09/40860336/marijuana-sales-hit-record-highs-in-these-6-us-states-is-marijuana-outpacing-alcohol"> strong demand</a> among connoisseurs.&#8221;
Chen also pointed out that Reddit's cannabis forums retain a grassroots, user-driven ethos. While the community provides honest feedback, brands cannot simply buy their way into the conversation.
&#8220;Brands need to engage authentically,&#8221; Chen concluded. &#8220;The community can spot a marketing ploy from a mile away. What resonates more is when a brand listens to user feedback and makes adjustments based on what people are saying on the forum.&#8221;
Read Next: <a href="https://www.benzinga.com/news/legal/24/11/41959036/trump-nominates-another-cannabis-supporter-to-cabinet-rep-matt-gaetz-for-attorney-general">Trump Nominates Another Cannabis Supporter To Cabinet: Rep. Matt Gaetz For Attorney General</a>

Cannabis

Social Media

Entrepreneurship

Retail Sales

Markets

Tech

Media

How Reddit's Cannabis Critics Are Helping Brands Spot Market Trends Before They Hit Dispensaries

Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) reported quarterly losses of $(1.43) per share. This is a 98.58 percent increase over losses of $(100.82) per share from the same period last year. The company reported $922.37 thousand in sales this quarter. This is a 27.55 percent increase over sales of $723.13 thousand the same period last year.

SCPX

Scorpius Holdings Q3 EPS $(1.43) Up From $(100.82) YoY, Sales $922.37K Up From $723.13K YoY

Fusion Fuel Green Plc ("Fusion Fuel" or the "Company") announced today that it has issued a damages claim against Hydrogenial S.A. ("Hydrogenial" or the "Investor") and its principal, Mr. Norbert Bindner, following their failure to fund the $33.5 million Subscription Agreement disclosed in the Company's Form 6-K on September 11, 2024. Under the terms of this agreement, entered into in good faith by the Company on August 28, 2024, the Investor committed to purchase an aggregate of 43,790,850 Class A ordinary shares (the "Class A Shares"), along with warrants to acquire an additional 13,137,254 Class A Shares, for a total purchase price of $33,500,000.
Pursuant to Section 3 of the Subscription Agreement, the closing was to take place on September 30, 2024, with full payment due at or before the time of the closing. Despite all conditions to closing being met, as confirmed in discussions with Hydrogenial representatives, the Investor failed to fund in a timely fashion. The Company promptly informed Hydrogenial of its breach and requested immediate resolution, and Hydrogenial subsequently provided the Company with a revised closing date of October 25, 2024; however, to date, the Company has yet to receive proceeds from the investment. This continued delay has led Fusion Fuel to pursue legal recourse.
As a direct consequence of the funding delay, Fusion Fuel has filed for insolvency for its Portuguese subsidiary, Fusion Fuel Portugal S.A., out of which the most significant portion of the Company's technology sales and project development activities had been conducted. On the advice of insolvency counsel, the Company has submitted a claim in Portugal for damages incurred due to Hydrogenial's breach. The Company notes that the Investor's obligation under the Subscription Agreement remains in effect notwithstanding the filing of the claim and the insolvency of its Portuguese subsidiary.
In response to these events, Fusion Fuel is actively exploring strategic alternatives to preserve shareholder value, including a potential transaction that management believes could complement the Company's hydrogen business and yield significant synergies. The Company expects to provide further updates in short order.

HTOO

Fusion Fuel Issues Damages Claim Against Hydrogenial S.A. For Failure To Fund $33.5M Subscription Agreement; Announces Insolvency Of Portuguese Subsidiary, Fusion Fuel Portugal S.A.; Fusion Fuel Is Actively Exploring Strategic Alternatives To Preserve Shareholder Value, Including A Potential Transaction That Management Believes Could Complement The Company's Hydrogen Business And Yield Significant Synergies

MNOV

MediciNova Receives Notice Of Allowance From US PTO For A Pending Patent Application For MN-001 (Tipelukast) To Cover 'Method To Decrease Triglyceride Synthesis In A Liver Of A Subject'

Swedish video game company Embracer Group AB's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/THQQF#OTC">THQQF</a>) latest financial results show a steep drop in sales and increased net losses as the company deals with game delays, staff <a href="https://www.benzinga.com/general/gaming">reductions, and restructuring.</a>
<h3 class="wp-block-heading">Q2 Financial Summary: Declining Sales And Higher Losses</h3>
For the quarter ending Sept. 30, Embracer reported (<a href="https://www.gamesindustry.biz/embracer-pc-and-console-sales-plummet-during-q2">via</a> GamesIndustry.biz) net sales of 8.55 billion SEK (about $774 million), down 21% from the same period last year.
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41985800/gta-5-joins-novembers-playstation-plus-lineup-with-other-fan-favorites">GTA 5 Joins November&#8217;s PlayStation Plus Lineup With Other Fan-Favorites</a>
Revenue from PC and console games took the largest hit, falling by 46% year-over-year to 2.12 billion SEK ($192 million), with only a few new releases and mixed reception of existing titles such as Disney Epic Mickey: Rebrushed. 
Mobile games saw an 8% decline, with revenue down to 1.35 billion SEK. The company recorded a net loss of 390 million SEK, a slight improvement from a 562 million SEK loss in the same quarter last year.
<h3 class="wp-block-heading">Six-Month Results: Losses And Reduced Workforce</h3>
Embracer's numbers for the first half of fiscal year 2025 reveal a sharper year-over-year decline. Net sales dropped 23% to 14.4 billion SEK, and its net loss widened to 2.58 billion SEK compared to a 1.69 billion SEK profit last year. 
Workforce reductions reflect the company's major restructuring efforts, with the number of game developers dropping from 10,654 to 6,250, and total headcount falling from 15,701 to 10,450.
<h3 class="wp-block-heading">Game Delays And Studio Divestments</h3>
A significant factor in Embracer's reduced revenues was a lack of major new releases and weaker-than-expected sales of its back catalog. 
Embracer also divested Gearbox and parts of Saber Interactive, affecting its revenue from older titles. CEO Lars Wingefors said, "Parts of our PC/Console and Entertainment &amp; Services segments are still underperforming due to delays and low ROI for primarily small and mid-sized releases." Embracer also recently sold Easybrain to Miniclip in a $1.2 billion deal as part of its efforts to reduce debt and streamline operations.
The company remains focused on core projects with a view toward longer-term growth, notably with the release of Kingdom Come: Deliverance 2, set to launch on Feb. 11, 2025, which Embracer expects will bring strong interest from the gaming community.
<h3 class="wp-block-heading">Outlook: Restructuring And Future Focus</h3>
Embracer anticipates continued lower earnings through the fiscal year, with Wingefors noting that the company has created "a stronger foundation for long-term value creation" by reducing debt and capital expenditures.
Embracer is also moving forward with plans to spin off Asmodee by the fiscal year-end, further refocusing its portfolio around core segments.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41909832/call-of-duty-black-ops-6s-pacifist-player-reaches-prestige-without-any-kills">Call Of Duty: Black Ops 6&#8217;s Pacifist Player Reaches Prestige Without Any Kills</a></li>
</ul>
Image credits: Shutterstock.

Gaming

General

THQQF

Embracer's Earnings Struggle As Game Delays, Restructuring Weigh On Results

Fortress Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIO#NASDAQ">FBIO</a>) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.15) by 33.91 percent. This is a 19.15 percent increase over losses of $(0.94) per share from the same period last year. The company reported quarterly sales of $14.63 million which missed the analyst consensus estimate of $32.22 million by 54.60 percent. This is a 57.90 percent decrease over sales of $34.75 million the same period last year.

FBIO

Fortress Biotech Q3 EPS $(0.76) Beats $(1.15) Estimate, Sales $14.63M Miss $32.22M Estimate

Operating expenses slashed by 22% year-over-year, falling to $3.9 million from $4.9 million in Q3 2023, reflecting efficiency gains.

WRAP

Wrap Technologies Reports Q3 Revenue Of $593K, Bringing 9-Month Revenue To $3.6M

BM Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMTX#AMEX">BMTX</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.20) by 110 percent. This is a 23.53 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $14.08 million which beat the analyst consensus estimate of $13.62 million by 3.36 percent. This is a 2.11 percent decrease over sales of $14.38 million the same period last year.

BMTX

BM Technologies Q3 Adj $(0.42) Misses $(0.20) Estimate, Sales $14.08M Beat $13.62M Estimate

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4303354-1&amp;h=1786564514&amp;u=http%3A%2F%2Fwww.standex.com%2F&amp;a=Standex+International+Corporation">Standex International Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) today announced that it has acquired Michigan-based Custom Biogenic Systems ("CBS") for approximately $6.2 million in cash. The transaction is being financed from Standex's existing cash balance. In its first year of ownership, the Company expects the acquisition to be accretive to its earnings. CBS will be reported as part of Standex's Scientific business segment.

Standex Acquires Custom Biogenic Systems For ~$6.2M In Cash

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Dogwood Therapeutics (DWTX – Research Report), retaining the price target of $25.0...

Strategic Merger Positions Dogwood Therapeutics for Success with Promising Pipeline and Financial Stability

Dogwood Therapeutics regains compliance with Nasdaq's minimum bid price rule

Dogwood (DWTX) Therapeutics has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The ...

Dogwood regains compliance with Nasdaq listing rule

Virios Therapeutics GAAP EPS of -$2.05

Virios Therapeutics, Inc. ( ($DWTX) ) has released its Q3 earnings. Here is a breakdown of the information Virios Therapeutics, Inc. presented to i...

Dogwood Therapeutics Reports Q3 2024 Financial Results

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Dogwood Therapeutics (DWTX – Research Report), with a pr...

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

Dogwood Therapeutics Inc (DWTX) has disclosed a new risk, in the Debt & Financing category. Dogwood Therapeutics Inc. faces a significant risk with...

Comments

Dogwood Therapeutics

Interés en corto

Dogwood Therapeutics (NASDAQ:DWTX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL